David Cosgrove

机构：Compass Oncology, Northwestern Medicine, The US Oncology Network, Nebraska Cancer Specialists · ORCID：0000-0003-2700-5656

发表论文 119 篇 · 总被引 8330 次 · h-index 39

代表论文

• Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial (2018 · The Lancet Oncology · 被引 2552)
• Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA (2020 · Annals of Oncology · 被引 1572)
• Pattern of distant metastases in colorectal cancer: a SEER based study (2015 · Oncotarget · 被引 257)
• Association Between Specific Mutations inKRASCodon 12 and Colorectal Liver Metastasis (2015 · JAMA Surgery · 被引 164)
• Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours (2016 · British Journal of Cancer · 被引 153)
• Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study (2023 · EClinicalMedicine · 被引 115)